Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic

J Ryan Bariola; Erin K McCreary; Tina Khadem; Graham M Snyder; Richard J Wadas; David A Nace; Douglas B White; Donald M Yealy; Mark Schmidhofer

doi:10.1093/ofid/ofab151

Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic

Open Forum Infect Dis. 2021 Mar 26;8(7):ofab151. doi: 10.1093/ofid/ofab151. eCollection 2021 Jul.

Authors

J Ryan Bariola¹, Erin K McCreary¹, Tina Khadem¹, Graham M Snyder¹, Richard J Wadas², David A Nace³, Douglas B White⁴, Donald M Yealy², Mark Schmidhofer⁵

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
² Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
³ Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
⁴ Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
⁵ Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Abstract

Emergency authorized coronavirus disease 2019 (COVID-19)-neutralizing monoclonal antibodies can aid outpatients with mild to moderate COVID-19 infection. Many report barriers to adequate distribution and uptake. We present our model for distribution in a large health system as well as early lessons learned.

Keywords: COVID-19; COVID-19 therapies; monoclonal antibodies.

Grants and funding

K24 HL148314/HL/NHLBI NIH HHS/United States